I’m-Yunity PSP: Canine Product Profile

I'm-Yunity is a named branded product for Dogs; manufacturer positioning must be kept separate from independent clinical evidence.

Vegetable capsules containing mushroom extract powder. Intended species: Dogs.

Purified Coriolus versicolor (Trametes versicolor) mushroom extract. The current official FAQ states polysaccharide peptide (PSP), with not less than 38% polysaccharide and 11.5% peptide per capsule.

The manufacturer presents the product as a standardized, single-species PSP extract for immune-health support and emphasizes its relationship to a University of Pennsylvania canine hemangiosarcoma study. Manufacturer descriptions such as “clinically proven” require a more precise account of the small exploratory study design.

May be discussed only as adjunctive/supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive goal, objective review date, adverse-effect plan, and stopping rule with the veterinarian.

Bring the current label, lot, complete ingredient panel, seller and country version, and every medicine and supplement to the treating veterinarian.

A published 2012 University of Pennsylvania dose-escalation pilot evaluated a PSP product in 15 dogs with naturally occurring splenic hemangiosarcoma after splenectomy. It reported signals involving metastasis and survival, but it was small, lacked a concurrent placebo or standard-treatment control group, and was intended to inform larger trials. It does not establish benefit for other cancers, other mushroom products, or every dog, and it is not equivalent to regulatory approval.

The manufacturer advises veterinary discussion, particularly with immunosuppressive medicines, autoimmune disease, or mushroom allergy. “No reported side effects” on a marketing FAQ cannot prove absence of risk. Product identity, batch quality, gastrointestinal tolerance, immune-modifying therapy, bleeding risk, liver or kidney disease, surgery, and concurrent supplements should be reviewed for the individual patient.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

Marketed in the United States as an animal herbal supplement and sold internationally. No FDA new-animal-drug approval was identified. Compliance claims about cGMP or contaminant testing concern manufacturing and do not establish clinical effectiveness.

United States; International

Confirm that the purchased bottle is the studied branded extract rather than a generic turkey-tail powder. Record lot, capsule strength, start date, appetite, stool, vomiting, skin signs, activity, body weight, and the oncology team’s objective disease measurements. Continue staging, imaging, blood counts, and other tumor-specific follow-up on schedule.